Working... Menu

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG (IMPACT-CABG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01033617
Recruitment Status : Completed
First Posted : December 16, 2009
Last Update Posted : October 18, 2017
Miltenyi Biotec, Inc.
Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Maisonneuve-Rosemont Hospital
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)